Rick Doblin on MDMA-Assisted Therapy for PTSD and FDA Approval Challenges

MDMA Therapy Studies and Timelines

• 🗓️ Studies for MDMA-assisted therapy for PTSD are ongoing, with a project in Israel involving about 160 people expected to take around three years.
• ⏳ The FDA approval process for MDMA-assisted therapy is complex, with the advisory committee and FDA initially voting against approval in August of the previous year, despite data demonstrating safety and efficacy.
• 💡 Modified group therapy approaches, where participants are brought together near the end of their individual sessions, are also being explored.

Challenges in Psychedelic Research: The Double-Blind Problem

• ❓ A significant challenge in psychedelic research is conducting double-blind studies, as participants are often aware they have taken a powerful drug.
• 🔬 Rick Doblin's dissertation proposed a solution: comparing low-dose MDMA therapy against full-dose MDMA therapy, ensuring all participants receive MDMA but varying the dosage.
• 📊 MAPS conducted phase 2 studies from 2000-2016, testing various MDMA doses (25mg to 150mg) to determine optimal therapeutic levels and understand dose-response relationships.

Dosage Findings and Therapeutic Effectiveness

• ⚠️ Early findings suggested that low doses (25-50mg) of MDMA, while causing some confusion, did not provide enough fear reduction for PTSD patients, making them uncomfortable and less effective than therapy with no MDMA.
• 🎯 A surprising discovery was that a 75mg dose appeared more therapeutic than a 125mg dose in a study with veterans, firefighters, and police officers, indicating the therapeutically effective dose might be lower than initially thought.
• ⚖️ The FDA ultimately chose therapy with an inactive placebo for phase 3 studies, making the research design more challenging but aiming to reduce experimental bias.

FDA Approval Process and Study Outcomes

• 📉 The FDA's decision to require independent, blind raters evaluating participants using the Clinician Administered PTSD Scale (CAPS) was a key part of the phase 3 design to mitigate bias.
• 🚀 The two phase 3 studies showed remarkable results: in severe PTSD, two-thirds of participants receiving MDMA-assisted therapy no longer had PTSD, compared to roughly one-third in the placebo group.
• ✅ In the second phase 3 study, 72.6% of participants with moderate to severe PTSD no longer had PTSD at two-month follow-up. Even the control group showed significant improvement, with 46% no longer meeting the PTSD threshold, highlighting the effectiveness of the therapeutic approach itself.
• ⏳ The timeline for potential FDA approval hinges on negotiations: if the FDA accepts the current data, approval could come within six months; if another phase 3 study is required, it could delay approval by another three and a half years.